Scientific Advisory Board
SickKids Scientific Advisory Board (SAB) is comprised of internationally respected research leaders. The SAB advises the Chief of Research, the CEO and the hospital’s board, in order to build on scientific excellence at SickKids. The SAB provides advice on the strategic direction of the Research Institute, helps to establish and monitor key performance indicators, provides feedback on the strengths and areas for development for the Research Institute and leads external reviews of the seven research programs.
SickKids Scientific Advisory Board members:
Dr. Stephen K. Burley, Director, Center for Integrative Proteomics Research, Associate Director, RCSB-PDB, Distinguished Professor, Department of Chemistry and Chemical Biology Member, Cancer Institute of New Jersey
Stephen Burley is an expert in structural biology and proteomics, structure/fragment based drug discovery, and clinical medicine/oncology. Burley currently serves as a Distinguished Professor in the Department of Chemistry and Chemical Biology and Director of the Center for Integrative Proteomics Research, and Director of the BioMaPS Institute for Quantitative Biology at Rutgers, The State University of New Jersey. He is also Associate Director of the Research Collaboratory for Structural Bioinformatics Protein Data Bank, and a Member of the Rutgers Cancer Institute of New Jersey. From 2008 to 2012, Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories.
Prior to joining Lilly, Burley served as the Chief Scientific Officer of SGX Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Lilly in 2008. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University, and an Investigator in the Howard Hughes Medical Institute. He has authored or coauthored more than 200 scholarly scientific articles. He is a Fellow of the Royal Society of Canada and of the New York Academy of Sciences. Burley received an MD degree from Harvard Medical School in the joint Harvard-MIT Health Sciences and Technology program and, as a Rhodes Scholar, received a D.Phil. in Molecular Biophysics (structural biology) from Oxford University. He trained in internal medicine at the Brigham and Women's Hospital, and did post-doctoral work with William N. Lipscomb at Harvard University and Gregory A. Petsko at the Massachusetts Institute of Technology. With William J. Rutter and others at the University of California, San Francisco and Rockefeller, Burley co-founded Prospect Genomics, Inc., which was acquired by SGX in 2001.
Dr. Martin Osmond, CEO and Scientific Director, Children’s Hospital of Eastern Ontario Research Institute (CHEO RI), Vice-President of Research, CHEO, Professor of Pediatrics, University of Ottawa and Senior Scientist, CHEO RI
Dr. Osmond graduated from McGill University medical school in 1986. He completed a Family Medicine Residency in 1988, and a Pediatric Residency in 1992 at the University of Ottawa. In 1994, he completed a Pediatric Emergency Fellowship at CHEO. His clinical work is as a pediatric emergency physician at CHEO
His areas of research interest are the evaluation and management of pediatric head injuries and the use of prehospital care in the treatment of ill and injured children. He is also a co-principal investigator in a CIHR-funded study of children with concussion presenting to the ED – this study aims to predict those who will suffer severe post-concussion syndrome in hopes of designing interventions for at-risk children to improve their outcomes.
Dr. Huda Y. Zoghbi, Professor, Departments of Molecular and Human Genetics, Pediatrics, Neurology, and Neuroscience, Baylor College of Medicine
Huda Zoghbi is Professor of Pediatrics, Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine and serves as an Investigator with the Howard Hughes Medical Institute. She is also the Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital.
Dr. Zoghbi’s interest is in using the tools of modern genetics to understand the proper development of the brain as well as what goes awry in specific neurodevelopmental and neurodegenerative conditions. She has published seminal work regarding the molecular basis of Rett syndrome and of late-onset neurodegenerative diseases. Dr. Zoghbi is a member of several professional organizations including the McKnight Foundation Neuroscience Board and the Lasker Jury and is a senior editor for the newly founded journal eLife. Among Dr. Zoghbi's honors are the E. Mead Johnson Award from Society of Pediatric Research, the IPSEN prize in neuronal plasticity, the Bristol Myers-Squibb Neuroscience Distinguished Achievement Award, the Vilcek Prize, and the Gruber prize in Neuroscience. In 2000 she was elected to the Institute of Medicine, and in 2004 she was elected to the National Academy of Sciences.